Literature DB >> 18625774

Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors.

Maria Simitsopoulou1, Emmanuel Roilides, Fotini Paliogianni, Christodoulos Likartsis, John Ioannidis, Kalliopi Kanellou, Thomas J Walsh.   

Abstract

Voriconazole (VRC) has activity against Aspergillus fumigatus, the most frequent cause of invasive aspergillosis in immunocompromised patients. The combination of VRC and A. fumigatus hyphae induced a more pronounced profile of expression of genes encoding inflammatory molecules in human monocytes than Aspergillus alone did. Herein, we provide further evidence of the potential mechanism underlying this immunomodulatory effect of VRC on human monocytes in response to A. fumigatus hyphae. A significant additive antifungal effect was shown when VRC was combined with monocytes against A. fumigatus hyphae. Both A. fumigatus hyphae and VRC induced pronounced profiles of mRNA and protein expression of Toll-like receptor 2 (TLR2) as well as tumor necrosis factor alpha (TNF-alpha) in THP-1 monocytic cells compared to untreated cells. The VRC-induced increase was greater than that induced by hyphae. The combination of VRC and hyphae increased mRNA and protein expression of TLR2 and TNF-alpha to even higher levels than did either VRC or hyphae alone. In contrast, TLR4 expression, both at the mRNA and protein levels, was not increased by either VRC or hyphae or their combination. In addition, significantly more NF-kappaB was translocated to the nuclei of THP-1 cells treated with VRC than untreated cells. While VRC induced more NF-kappaB than hyphae did, treatment with the combination of the two factors induced the greatest NF-kappaB expression. The pronounced profile of TLR2 signaling, TNF-alpha expression, and NF-kappaB activation in the presence of VRC suggests an immunomodulatory effect leading to a more efficient response to A. fumigatus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625774      PMCID: PMC2533507          DOI: 10.1128/AAC.01018-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae.

Authors:  J E Wang; A Warris; E A Ellingsen; P F Jørgensen; T H Flo; T Espevik; R Solberg; P E Verweij; A O Aasen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus.

Authors:  M Simitsopoulou; E Roilides; C Likartsis; J Ioannidis; A Orfanou; F Paliogianni; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-12-18       Impact factor: 5.191

3.  Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages.

Authors:  Lawrence H Bopp; Aldona L Baltch; William J Ritz; Phyllis B Michelsen; Raymond P Smith
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

4.  Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis.

Authors:  S Kaur; V K Gupta; S Thiel; P U Sarma; T Madan
Journal:  Clin Exp Immunol       Date:  2007-03-05       Impact factor: 4.330

5.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

6.  Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus.

Authors:  Salamatu S Mambula; Keya Sau; Philipp Henneke; Douglas T Golenbock; Stuart M Levitz
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

7.  Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages.

Authors:  A Meier; C J Kirschning; T Nikolaus; H Wagner; J Heesemann; F Ebel
Journal:  Cell Microbiol       Date:  2003-08       Impact factor: 3.715

8.  Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000.

Authors:  Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach
Journal:  Pediatrics       Date:  2006-03-13       Impact factor: 7.124

9.  Pseudomonas aeruginosa slime glycolipoprotein is a potent stimulant of tumor necrosis factor alpha gene expression and activation of transcription activators nuclear factor kappa B and activator protein 1 in human monocytes.

Authors:  George Lagoumintzis; Myrto Christofidou; George Dimitracopoulos; Fotini Paliogianni
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 10.  Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromized hosts.

Authors:  Michel Chignard; Viviane Balloy; Jean-Michel Sallenave; Mustapha Si-Tahar
Journal:  Clin Immunol       Date:  2007-07-02       Impact factor: 3.969

View more
  18 in total

1.  Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

Authors:  Silvia Moretti; Silvia Bozza; Carmen D'Angelo; Andrea Casagrande; Maria Agnese Della Fazia; Lucia Pitzurra; Luigina Romani; Franco Aversa
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Eradication of the commensal intestinal microflora by oral antimicrobials interferes with the host response to lipopolysaccharide.

Authors:  T Umenai; H Hirai; N Shime; T Nakaya; T Asahara; K Nomoto; M Kita; Y Tanaka; J Imanishi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-20       Impact factor: 3.267

Review 3.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

4.  Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis.

Authors:  Pietro Lo Giudice; Silvia Campo; Rita De Santis; Giovanni Salvatori
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

5.  Efficacy of Voriconazole against Aspergillus fumigatus Infection Depends on Host Immune Function.

Authors:  Emily E Rosowski; Jiaye He; Jan Huisken; Nancy P Keller; Anna Huttenlocher
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

6.  In vitro and in vivo study on the effect of antifungal agents on hematopoietic cells in mice.

Authors:  Maria Samalidou; Dimitris Bougiouklis; Timoleon-Achilleas Vyzantiadis; Joseph Meletiadis; Nikolaos Monokrousos; Eleni Siotou; Afroditi Sivropoulou; Achilles Anagnostopoulos; Damianos Sotiropoulos
Journal:  Exp Biol Med (Maywood)       Date:  2015-06-16

7.  Treatment options in Invasive Aspergillosis.

Authors:  Anil A Panackal; John E Bennett; Peter R Williamson
Journal:  Curr Treat Options Infect Dis       Date:  2014-09

8.  Antifungal Drugs Influence Neutrophil Effector Functions.

Authors:  Frederic Ries; Astrid Alflen; Pamela Aranda Lopez; Hendrik Beckert; Matthias Theobald; Hansjörg Schild; Daniel Teschner; Markus Philipp Radsak
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

9.  Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis.

Authors:  Stacy J Park; Molly A Hughes; Marie Burdick; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

10.  Modulation of Toll-like receptor 2 (TLR2) and TLR4 responses by Aspergillus fumigatus.

Authors:  Louis Y A Chai; Bart Jan Kullberg; Alieke G Vonk; Adilia Warris; Alessandra Cambi; Jean-Paul Latgé; Leo A B Joosten; Jos W M van der Meer; Mihai G Netea
Journal:  Infect Immun       Date:  2009-02-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.